PRA Health Sciences supported 2 multiple myeloma clinical trials, a Phase III and a “rollover,” for a large biotech client. This management contract was one of the largest on record in the ongoing research for multiple myeloma treatment. PRA’s clinical team provided enhanced communication and site support, enabling PRA to streamline regulatory document collection to quickly activate sites. Approved by the FDA after a 4-month accelerated approval process, the drug is the first in a new class of anti-cancer agents called proteasome inhibitors.
PRA Health Sciences Investor Relations
We’re in the business of improving lives, but drug development isn’t the only way we’re doing it. While bringing new treatments to market is…
PRA Cool Under Deadline Pressure
PRA was selected to perform a Phase II colorectal cancer trial due to our knowledge from previous colorectal studies as well as our evidence-based…